{"id":"https://openalex.org/W3029023398","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3146","title":"Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.","display_name":"Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.","alternate_titles":[],"publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3029023398","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3146","mag":"3029023398"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.tps3146","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3146","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3146","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3029023398"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078038970","display_name":"Jayesh Desai","orcid":"https://orcid.org/0000-0003-4246-9344","observed_orcids":["https://orcid.org/0000-0003-4246-9344"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jayesh Desai","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, Australia;","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073719611","display_name":"Tarek M. Meniawy","orcid":"https://orcid.org/0000-0002-1457-6137","observed_orcids":["https://orcid.org/0000-0002-1457-6137"]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I4210156497","display_name":"Linear Clinical Research","ror":"https://ror.org/05vnpr825","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4210156497"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Tarek Meniawy","raw_affiliation_strings":["Linear Clinical Research and University of Western Australia, Nedlands, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Linear Clinical Research and University of Western Australia, Nedlands, Australia;","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I4210156497"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090842462","display_name":"Brandon R. Beagle","orcid":"https://orcid.org/0009-0003-6397-7548","observed_orcids":["https://orcid.org/0009-0003-6397-7548"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandon Beagle","raw_affiliation_strings":["BeiGene USA, Inc., San Mateo, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BeiGene USA, Inc., San Mateo, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006313328","display_name":"Zhezhen Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ZheZhen Li","raw_affiliation_strings":["BeiGene (Shanghai) Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BeiGene (Shanghai) Co., Ltd., Shanghai, China;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050035595","display_name":"Song Mu","orcid":"https://orcid.org/0009-0008-1929-0286","observed_orcids":["https://orcid.org/0009-0008-1929-0286"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Song Mu","raw_affiliation_strings":["BeiGene USA, Inc., San Mateo, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BeiGene USA, Inc., San Mateo, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075203835","display_name":"John C. Wu","orcid":"https://orcid.org/0000-0001-7990-7139","observed_orcids":["https://orcid.org/0000-0001-7990-7139"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Wu","raw_affiliation_strings":["BeiGene USA, Inc., San Mateo, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BeiGene USA, Inc., San Mateo, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005375804","display_name":"Crystal Shereen Denlinger","orcid":"https://orcid.org/0000-0002-5663-7751","observed_orcids":["https://orcid.org/0000-0002-5663-7751"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Crystal S. Denlinger","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, PA;","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078259926","display_name":"Wells A. Messersmith","orcid":"https://orcid.org/0000-0003-2349-0885","observed_orcids":["https://orcid.org/0000-0003-2349-0885"]},"institutions":[{"id":"https://openalex.org/I4210087413","display_name":"University of Colorado Health","ror":"https://ror.org/0107w4315","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087413"]},{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I51713134","display_name":"University of Colorado Anschutz","ror":"https://ror.org/03wmf1y16","country_code":"US","type":"education","lineage":["https://openalex.org/I51713134"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wells A. Messersmith","raw_affiliation_strings":["UCHealth Cancer Care-Anschutz Medical Campus-University of Colorado Cancer Center, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCHealth Cancer Care-Anschutz Medical Campus-University of Colorado Cancer Center, Aurora, CO;","institution_ids":["https://openalex.org/I4210087413","https://openalex.org/I4210134151","https://openalex.org/I51713134"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"TPS3146","last_page":"TPS3146"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tislelizumab","display_name":"tislelizumab","score":0.9380000233650208},{"id":"https://openalex.org/keywords/tim-3","display_name":"TIM-3","score":0.8569999933242798},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8669999837875366},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8100000023841858},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/antibody-dependent-phagocytosis","display_name":"antibody-dependent phagocytosis","score":0.8100000023841858},{"id":"https://openalex.org/keywords/fc-gamma-receptor","display_name":"Fc gamma receptor","score":0.6520000100135803},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.8190000057220459},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7239999771118164},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8320000171661377},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9829999804496765},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.7459999918937683},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.6779999732971191},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.4050000011920929}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7159947156906128},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6706860065460205},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.592134416103363},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.586752712726593},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5254579782485962},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5181454420089722},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4992351531982422},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.48072364926338196},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.44129958748817444},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.4412175416946411},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3976183533668518},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2953011691570282},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25847092270851135},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.18705043196678162},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.1294652819633484}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.tps3146","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3146","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3146","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:publications/526b9e44-95aa-4f06-ac6f-cc60b6cd41f1","doi":null,"is_oa":false,"landing_page_url":"https://research-repository.uwa.edu.au/en/publications/526b9e44-95aa-4f06-ac6f-cc60b6cd41f1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402492","display_name":"UWA Profiles and Research Repository (UWA)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Desai, J, Meniawy, T, Beagle, B, Li, Z, Mu, S, Wu, J, Denlinger, C S & Messersmith, W A 2020, 'Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors : A phase I/II trial in progress.', Journal of Clinical Oncology, vol. 38, no. 15.","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2891809995","https://openalex.org/W2898395976","https://openalex.org/W3058609909","https://openalex.org/W2947134781","https://openalex.org/W4379283597","https://openalex.org/W4414937742","https://openalex.org/W4393093922","https://openalex.org/W4379283213","https://openalex.org/W2959586017","https://openalex.org/W4321083638"],"abstract_inverted_index":{"TPS3146":[0],"Background:":[1],"While":[2],"immune":[3,24,40,66,81],"surveillance":[4],"plays":[5],"a":[6,63,123,241],"critical":[7],"role":[8],"in":[9,47,77,117,150,154,171,175,208,232,296,305],"preventing":[10],"tumor":[11,210,303],"proliferation":[12],"and":[13,28,32,49,53,128,145,274,280,310,315,334],"metastasis,":[14],"tumors":[15],"develop":[16],"resistance":[17,130],"mechanisms":[18],"to":[19,56,62,75,110,113,119,131,216,298],"suppress":[20],"and/or":[21],"escape":[22],"the":[23,88,140,189,202,206,286,290],"system.":[25],"T-cell":[26,59,126],"immunoglobulin":[27],"mucin-domain":[29],"containing-3":[30],"(TIM-3)":[31],"programmed":[33],"cell":[34],"death":[35],"protein-1":[36],"(PD-1)":[37],"function":[38,50],"as":[39],"checkpoint":[41],"receptors":[42],"on":[43,115,240,253,260,277],"tumor-infiltrating":[44],"lymphocytes.":[45],"Overlap":[46],"expression":[48],"suggests":[51],"TIM-3":[52,71],"PD-1":[54],"cooperate":[55],"maximize":[57],"effector":[58],"exhaustion,":[60],"leading":[61],"decreased":[64],"antitumor":[65,80,89,146,203,330],"response.":[67],"Although":[68],"blockade":[69,85],"of":[70,91,125,148,169,205,225,228,336],"alone":[72,252,259],"is":[73,96,162,288],"unlikely":[74],"result":[76],"an":[78,97,105,163],"efficacious":[79],"response,":[82],"combined":[83],"TIM-3/PD-1":[84],"may":[86],"enhance":[87],"properties":[90],"anti-PD-1":[92,106,132],"therapies":[93],"alone.":[94],"BGB-A425":[95,149,170,231,251,273],"investigational":[98],"IgG1-variant":[99],"monoclonal":[100],"antibody":[101],"against":[102],"TIM-3.":[103],"Tislelizumab,":[104],"antibody,":[107],"was":[108],"engineered":[109],"minimize":[111],"binding":[112],"Fc\u0263R":[114],"macrophages":[116],"order":[118],"abrogate":[120],"antibody-dependent":[121],"phagocytosis,":[122],"mechanism":[124],"clearance":[127],"potential":[129],"therapy.":[133,338],"This":[134,161],"phase":[135,165,191,198,213,306],"1/2":[136,166],"study":[137,167,243],"will":[138,187,200,219,249,270,293],"assess":[139,201],"safety/tolerability,":[141],"pharmacokinetic":[142],"(PK)":[143],"profile,":[144,333],"activity":[147],"combination":[151,172,196,207,233,291,337],"with":[152,156,173,177,234,301],"tislelizumab":[153,174,235,258,275],"patients":[155,176,218,248,269,300],"advanced":[157],"solid":[158,183],"tumors.":[159,184],"Methods:":[160],"open-label":[164],"(NCT03744468)":[168],"histologically/cytologically":[178],"confirmed":[179],"advanced,":[180],"metastatic,":[181],"unresectable":[182],"Phase":[185],"1":[186,255],"determine":[188],"recommended":[190],"2":[192,199],"dose":[193],"(RP2D)":[194],"for":[195],"treatment;":[197],"effects":[204],"select":[209,302],"types.":[211],"In":[212],"1,":[214,247],"up":[215,297],"42":[217],"be":[220,294],"enrolled":[221],"into":[222],"sequential":[223],"cohorts":[224],"increasing":[226],"doses":[227],"intravenous":[229],"(IV)":[230],"200":[236],"mg":[237],"IV,":[238],"based":[239],"3+3":[242],"design.":[244],"During":[245],"Cycle":[246],"receive":[250,271],"Day":[254,261,278],"followed":[256],"by":[257],"8.":[262],"If":[263],"no":[264],"dose-limiting":[265],"toxicities":[266],"are":[267,324],"observed,":[268],"both":[272],"sequentially":[276],"29":[279],"every":[281],"21":[282],"days":[283],"thereafter.":[284],"Once":[285],"RP2D":[287,311],"determined,":[289],"therapy":[292],"evaluated":[295],"120":[299],"types":[304],"2.":[307],"Safety/tolerability":[308],"profile":[309],"determination":[312],"(phase":[313,322],"1)":[314],"objective":[316],"response":[317],"rate":[318],"per":[319],"RECIST":[320],"v1.1":[321],"2)":[323],"primary":[325],"objectives;":[326],"secondary":[327],"objectives":[328],"include":[329],"activity,":[331],"PK":[332],"immunogenicity":[335],"Clinical":[339],"trial":[340],"information:":[341],"NCT03744468":[342],".":[343]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3029023398","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2020-06-05T00:00:00"}
